MSN Labs’ generic Zytiga receives FDA approval
MSN Labs, the parent company of Novadoz Pharmaceuticals, has received the Food and Drug Administration’s nod for abiraterone acetate 250 mg tablets.
The product is the generic of Janssen Pharmaceuticals' Zytiga, and indicated for the treatment of prostate cancer when used with a steroid medication (prednisone or methylprednisolone).
In addition, abiraterone acetate is available in 120 tablet count bottles.
“The approval of generic abiraterone is significant for our organization as it continues to fill our portfolio with important products, most specifically those used in the oncology class. These products offer great value to patients and our customers and continue to build on Novadoz's successful entrance in the U.S market. We are continuing to focus on our plans to launch 10 to 12 additional products in the next 12 to 18 months," Novadoz president, N.A generics, Seshu Akula said.
The product is the generic of Janssen Pharmaceuticals' Zytiga, and indicated for the treatment of prostate cancer when used with a steroid medication (prednisone or methylprednisolone).
In addition, abiraterone acetate is available in 120 tablet count bottles.
“The approval of generic abiraterone is significant for our organization as it continues to fill our portfolio with important products, most specifically those used in the oncology class. These products offer great value to patients and our customers and continue to build on Novadoz's successful entrance in the U.S market. We are continuing to focus on our plans to launch 10 to 12 additional products in the next 12 to 18 months," Novadoz president, N.A generics, Seshu Akula said.